Literature DB >> 18410240

The therapeutic potential of neuronal K V 7 (KCNQ) channel modulators: an update.

Valentin K Gribkoff1.   

Abstract

BACKGROUND: Neuronal KCNQ channels (K(V)7.2-5) represent attractive targets for the development of therapeutics for chronic and neuropathic pain, migraine, epilepsy and other neuronal hyperexcitability disorders, although there has been only modest progress in translating this potential into useful therapeutics.
OBJECTIVE: Compelling evidence of the importance of K(V)7 channels as neuronal regulatory elements, readily amenable to pharmacological modulation, has sustained widespread interest in these channels as drug targets. This review will update readers on key aspects of the characterization of these important ion channel targets, and will discuss possible current barriers to their exploitation for CNS therapeutics.
METHODS: This article is based on a review of recent literature, with a focus on data pertaining to the roles of these channels in neurophysiology. In addition, I review some of the regulatory elements that influence the channels and how these may relate to channel pharmacology, and present a review of recent advances in neuronal K(V)7 channel pharmacology.
CONCLUSIONS: These channels continue to be valid and approachable targets for CNS therapeutics. However, we may need to understand more about the roles of neuronal K(V)7 channels during the development of disease states, as well as to pay more attention to a detailed analysis of the molecular pharmacology of the different channel subfamily members and the modes of interaction of individual modulators, in order to successfully target these channels for therapeutic development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18410240     DOI: 10.1517/14728222.12.5.565

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  17 in total

1.  Discovery, Synthesis, and Structure Activity Relationship of a Series of N-Aryl- bicyclo[2.2.1]heptane-2-carboxamides: Characterization of ML213 as a Novel KCNQ2 and KCNQ4 Potassium Channel Opener.

Authors:  Haibo Yu; Meng Wu; Steven D Townsend; Beiyan Zou; Shunyou Long; J Scott Daniels; Owen B McManus; Min Li; Craig W Lindsley; Corey R Hopkins
Journal:  ACS Chem Neurosci       Date:  2011-10-19       Impact factor: 4.418

Review 2.  Headache-type adverse effects of NO donors: vasodilation and beyond.

Authors:  G Bagdy; P Riba; V Kecskeméti; D Chase; G Juhász
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

3.  From pan-reactive KV7 channel opener to subtype selective opener/inhibitor by addition of a methyl group.

Authors:  Sigrid Marie Blom; Mario Rottländer; Jan Kehler; Christoffer Bundgaard; Nicole Schmitt; Henrik Sindal Jensen
Journal:  PLoS One       Date:  2014-06-23       Impact factor: 3.240

4.  KCNQ (Kv7) potassium channel activators as bronchodilators: combination with a β2-adrenergic agonist enhances relaxation of rat airways.

Authors:  Lioubov I Brueggemann; Jennifer M Haick; Samantha Neuburg; Shawn Tate; Devjit Randhawa; Leanne L Cribbs; Kenneth L Byron
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-01-17       Impact factor: 5.464

5.  N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy.

Authors:  George Amato; Rosemarie Roeloffs; Greg C Rigdon; Brett Antonio; Theresa Mersch; Grant McNaughton-Smith; Alan D Wickenden; Paul Fritch; Mark J Suto
Journal:  ACS Med Chem Lett       Date:  2011-03-31       Impact factor: 4.345

6.  M channel enhancers and physiological M channel block.

Authors:  John E Linley; Louisa Pettinger; Dongyang Huang; Nikita Gamper
Journal:  J Physiol       Date:  2011-12-12       Impact factor: 5.182

Review 7.  Neural KCNQ (Kv7) channels.

Authors:  David A Brown; Gayle M Passmore
Journal:  Br J Pharmacol       Date:  2009-03-09       Impact factor: 8.739

Review 8.  The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes.

Authors:  Valentin K Gribkoff; Leonard K Kaczmarek
Journal:  Neuropharmacology       Date:  2016-03-12       Impact factor: 5.250

Review 9.  Ion channel regulation by β-secretase BACE1 - enzymatic and non-enzymatic effects beyond Alzheimer's disease.

Authors:  Sandra Lehnert; Stephanie Hartmann; Sabine Hessler; Helmuth Adelsberger; Tobias Huth; Christian Alzheimer
Journal:  Channels (Austin)       Date:  2016-06-02       Impact factor: 2.581

10.  High-throughput behavioral phenotyping in the expanded panel of BXD recombinant inbred strains.

Authors:  V M Philip; S Duvvuru; B Gomero; T A Ansah; C D Blaha; M N Cook; K M Hamre; W R Lariviere; D B Matthews; G Mittleman; D Goldowitz; E J Chesler
Journal:  Genes Brain Behav       Date:  2009-09-22       Impact factor: 3.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.